Armata Pharmaceuticals said it received an additional $3.7 million in non-dilutive funds from the Defense Department to continue developing a treatment for a type of bacterial infection.

The biotechnology company said Wednesday it will use the funding for the Phase 3 clinical program for AP-SA02, its lead clinical candidate that is in development as an adjunctive treatment for complicated staphylococcus aureus bacteremia (SAB).

The Defense Department previously provided $28.7 million to support AP-SA02. The company said it sees the latest funding as the Defense Department's first commitment of support for the Phase 3 program.

"We intend to continue working closely with the DoW regarding potential additional support as the Phase 3 study advances," Chief Executive Deborah Birx said.

Birx said complicated SAB is associated with substantial morbidity and mortality in both military and civilian populations.